Vitamin K2 and Cardiovascular Calcification: Mechanistic Foundations, Conflicting Clinical Evidence, and Unresolved Questions
- 1Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH 44195, USA
- 2Department of Internal Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
- 3Department of Medicine, Cardiometabolic & Endocrine Institute, North Brunswick, NJ 08902, USA
Abstract
Cardiovascular calcification is an active, complex process involving osteogenic transformation, inflammation, extracellular vesicle release, and impaired mineral buffering. These changes result from mineral imbalance and reduced levels of calcification inhibitors. Vitamin K supports the γ-carboxylation of matrix Gla protein (MGP) and other mineralization inhibitors, though some calcification defenses do not depend on vitamin K. Vitamin K deficiency and warfarin therapy increase circulating dephosphorylated-uncarboxylated MGP (dp-ucMGP), which is linked to greater vascular calcification. Preclinical studies demonstrate that disruption of the vitamin K-MGP axis promotes calcification. Supplementation with vitamin K1 or K2 can reduce, prevent, or partially reverse mineralization in certain animal models. In contrast, evidence from human studies is less consistent. Observational studies have identified an association between menaquinone (vitamin K2) intake and cardiovascular outcomes, but causality has not been established. Most randomized trials have shown neutral results for aortic-valve and chronic kidney disease-associated calcification, while the VitaK-CAC and DANCODE studies reported slower progression of coronary artery calcium in selected populations with moderate or severe baseline coronary calcification. These discrepancies may be due to differences in calcification phenotypes, disease stage, vitamin K forms, dosing regimens, vitamin D status, renal function, and response to vitamin K antagonists such as warfarin. Coronary intimal, valvular, and arterial medial calcification should be regarded as phenotypically distinct entities. This review evaluates the mechanistic, preclinical, and clinical evidence linking vitamin K2 to cardiovascular calcification and highlights population groups that warrant further clinical investigation. Large, adequately powered, and phenotype-specific clinical trials are needed to determine whether appropriately dosed vitamin K2 is a safe and cost-effective intervention for slowing valvular and vascular calcification.
Related
- Mechanistic insight into conflicting valence fluctuation of Cu(I) photocorrosion pathways: The role of charge behaviors
- Panax ginseng Across the Cardiovascular Continuum: Molecular Targets, Mechanistic Convergence, and Translational Challenges
- Natural Products and Their Derivatives in Cancer, Cardiovascular disease, and COVID-19: Mechanistic Insights, Formulation Strategies, and Therapeutic Potential
- Signal Additivity as a Practical Criterion for Validating Kd Determination: Reconciling Conflicting Backscattering Interferometry Results
- The gut–bone axis in osteoporosis: microbial mechanisms, conflicting evidence, and translational priorities
BibTeX
@article{kothari2026vitamin,
title = {{Vitamin K2 and Cardiovascular Calcification: Mechanistic Foundations, Conflicting Clinical Evidence, and Unresolved Questions}},
author = {Chinmayi Kothari and Rahul Chowdhary and Sada Babazade and Alexander Egoavil and Wajeh Abuirmaileh and Samir R. Kapadia and Sunil J. Wimalawansa},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = oct,
doi = {10.3390/ijms27219645},
url = {https://www.mdpi.com/1422-0067/27/21/9645},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Vitamin K2 and Cardiovascular Calcification: Mechanistic Foundations, Conflicting Clinical Evidence, and Unresolved Questions
AU - Chinmayi Kothari
AU - Rahul Chowdhary
AU - Sada Babazade
AU - Alexander Egoavil
AU - Wajeh Abuirmaileh
AU - Samir R. Kapadia
AU - Sunil J. Wimalawansa
PY - 2026
DA - 2026/10/28
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27219645
UR - https://www.mdpi.com/1422-0067/27/21/9645
AB - Cardiovascular calcification is an active, complex process involving osteogenic transformation, inflammation, extracellular vesicle release, and impaired mineral buffering. These changes result from mineral imbalance and reduced levels of calcification inhibitors. Vitamin K supports the γ-carboxylation of matrix Gla protein (MGP) and other mineralization inhibitors, though some calcification defenses do not depend on vitamin K. Vitamin K deficiency and warfarin therapy increase circulating dephosphorylated-uncarboxylated MGP (dp-ucMGP), which is linked to greater vascular calcification. Preclinical studies demonstrate that disruption of the vitamin K-MGP axis promotes calcification. Supplementation with vitamin K1 or K2 can reduce, prevent, or partially reverse mineralization in certain animal models. In contrast, evidence from human studies is less consistent. Observational studies have identified an association between menaquinone (vitamin K2) intake and cardiovascular outcomes, but causality has not been established. Most randomized trials have shown neutral results for aortic-valve and chronic kidney disease-associated calcification, while the VitaK-CAC and DANCODE studies reported slower progression of coronary artery calcium in selected populations with moderate or severe baseline coronary calcification. These discrepancies may be due to differences in calcification phenotypes, disease stage, vitamin K forms, dosing regimens, vitamin D status, renal function, and response to vitamin K antagonists such as warfarin. Coronary intimal, valvular, and arterial medial calcification should be regarded as phenotypically distinct entities. This review evaluates the mechanistic, preclinical, and clinical evidence linking vitamin K2 to cardiovascular calcification and highlights population groups that warrant further clinical investigation. Large, adequately powered, and phenotype-specific clinical trials are needed to determine whether appropriately dosed vitamin K2 is a safe and cost-effective intervention for slowing valvular and vascular calcification.
SN - 1422-0067
ER -